RECEPTOR BINDING DOMAIN FUSION HETERODIMER clinical trials

A Phase IIb/III, Double-Blind, Randomised, Active-Controlled, Multi-Center, Non-Inferiority Clinical Trial, to assess the safety and immunogenicity of a booster vaccination with an adapted recombinant protein RBD fusion homodimer candidate (PHH-1V81) against SARS-CoV-2, in adults vaccinated against COVID-19.

This study is testing a new COVID-19 booster vaccine (PHH-1V81) to see how safe it is and how well it helps your body fight the virus. It compares the new booster to a current COVID-19 vaccine in adults who have already been vaccinated.